CD84 is Markedly Upregulated in Kawasaki Disease Arteriopathy.
Chicago, United States. In Clin Exp Immunol, 17 Apr 2014
METHODS: To identify dysregulated gene expression in KD CA, we performed high-throughput RNA sequencing on KD and control CA, validated potentially dysregulated genes by real-time RT-PCR, and localized protein expression by immunohistochemistry. RESULTS: Signaling lymphocyte activation molecule CD84 was upregulated 16-fold (p<0.01) in acute KD CA (within 2 months of onset) and 32-fold (p<0.01) in chronic CA (5 months to years after onset).
Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.
Sydney, Australia. In Leuk Lymphoma, 24 Feb 2014
Using an extended DotScan(™) CLL antibody microarray (Version 3; 182 CD antibodies), and with refined analysis of purified CD19 + B-cells, the following 27 CD antigens were differentially abundant for progressive CLL: CD11a, CD11b, CD11c, CD18, CD19, CD20 (two epitopes), CD21, CD22, CD23, CD24, CD25, CD38, CD40, CD43, CD45, CD45RA, CD52, CD69, CD81, CD84, CD98, CD102, CD148, CD180, CD196 and CD270.
Proteomic analysis of human osteoarthritis synovial fluid.
Pune, India. In Clin Proteomics, Dec 2013
These novel proteins included ADAM-like decysin 1 (ADAMDEC1), alanyl (membrane) aminopeptidase (ANPEP), CD84, fibulin 1 (FBLN1), matrix remodelling associated 5 (MXRA5), secreted phosphoprotein 2 (SPP2) and spondin 2 (SPON2).
[Some considerations of immune metabolism at preeclampsia].
In Georgian Med News, 2011
In peripheral blood serum of all pregnant women at 20th week of gestation relative content of T-lymphocyte subpopulations, active T-lymphocytes and natural killers (NK) were detected by the method of indirect immunofluorescence and in cyto-toxic test using monoclonal antibodies to CD4 and CD84, CD 16 (T-cell markers of HLA-DR antigen of second class of MHC (marker of active T-lymphocytes, "ICN Pharmaceutical", USA).
The role of SLAM/CD2 polymorphisms in systemic autoimmunity.
Dallas, United States. In Curr Opin Immunol, 2010
Three members of this gene family, Ly108, Ly9, and CD84, exhibit polymorphisms that strongly influence susceptibility to systemic autoimmunity, notably in mice, but also in some human populations.
SLAM family receptors and SAP adaptors in immunity.
Bethesda, United States. In Annu Rev Immunol, 2010
The signaling lymphocyte activation molecule (SLAM)-associated protein, SAP, was first identified as the protein affected in most cases of X-linked lymphoproliferative (XLP) syndrome, a rare genetic disorder characterized by abnormal responses to Epstein-Barr virus infection, lymphoproliferative syndromes, and dysgammaglobulinemia. SAP consists almost entirely of a single SH2 protein domain that interacts with the cytoplasmic tail of SLAM and related receptors, including 2B4, Ly108, CD84, Ly9, and potentially CRACC.
Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules.
Australia. In Annu Rev Immunol, 2006
During the past eight years, it has been established that the SLAM family of cell surface receptors (SLAM, 2B4, NTB-A, Ly9, CD84) and the SAP family of adaptors (SAP, EAT-2, ERT) play critical roles in lymphocyte development, differentiation, and acquisition of effector functions.
Novel targets for antithrombotic drug discovery.
San Francisco, United States. In Blood Cells Mol Dis, 2006
Recent data using proteomics and genomics strategies have established that signaling pathways during platelet aggregation are triggered by two homophilic adhesion molecules, CD84 and CD150 (SLAM), and by a novel EGF-containing receptor, PEAR1, which are tyrosine-phosphorylated in a platelet-aggregation-dependent fashion (N.
Molecular and cellular pathogenesis of X-linked lymphoproliferative disease.
Philadelphia, United States. In Immunol Rev, 2005
SAP is expressed in T cells, natural killer (NK) cells, and NKT cells, where it binds to the cytoplasmic domain of the surface receptor SLAM (CD150) and the related receptors, 2B4 (CD244), CD84, Ly9 (CD229), NK-T-B-antigen, and CD2-like receptor-activating cytotoxic T cells.